Skip to main content

Table 3 Associations between molecular subtypes and clinicopathologic variables in the validation cohort

From: Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations

VariableNOverallsTRU
(n = 74)
sPP
(n = 102)
sPI
(n = 83)
EGFR/TP53
(n = 74)
KRAS/TP53
(n = 50)
Non-TRUPPPI
(n = 38)
No mutation
(n = 63)
P
Age, mean (standard deviation), y48463.7 (10.4)66.4 (9.1)65.9 (9.4)63.2 (9.3)59.1 (11.9)64.1 (8.5)63.7 (11.7)62.7 (12.2)< 0.001
Race/ethnicity, n (%)484        < 0.001a
 Asian 40 (8.3)13 (17.6)2 (2.0)4 (4.8)14 (18.9)0 (0.0)1 (2.6)6 (9.5) 
 Black 36 (7.4)2 (2.7)11 (10.8)6 (7.2)6 (8.1)3 (6.0)2 (5.3)6 (9.5) 
 White 372 (76.9)54 (73.0)80 (78.4)71 (85.5)44 (59.5)40 (80.0)35 (92.1)48 (76.2) 
 Hispanic 31 (6.4)5 (6.8)8 (7.8)2 (2.4)7 (9.5)6 (12.0)0 (0.0)3 (4.8) 
 Other 5 (1.0)0 (0.0)1 (1.0)0 (0.0)3 (4.1)1 (2.0)0 (0.0)0 (0.0) 
Sex, n (%)484        0.022
 Female 280 (57.9)49 (66.2)65 (63.7)37 (44.6)43 (58.1)32 (64.0)25 (65.8)29 (46.0) 
 Male 204 (42.1)25 (33.8)37 (36.3)46 (55.4)31 (41.9)18 (36.0)13 (34.2)34 (54.0) 
Smoking, n (%)484        < 0.001a
 Current 60 (12.4)2 (2.7)22 (21.6)14 (16.9)4 (5.4)8 (16.0)3 (7.9)7 (11.1) 
 Former 270 (55.8)26 (35.1)69 (67.6)55 (66.3)29 (39.2)39 (78.0)25 (65.8)27 (42.9) 
 Never 154 (31.8)46 (62.2)11 (10.8)14 (16.9)41 (55.4)3 (6.0)10 (26.3)29 (46.0) 
Alcohol, n (%)478        0.476a
 Current 174 (36.4)30 (41.1)36 (35.3)29 (36.2)26 (35.1)16 (32.0)16 (42.1)21 (34.4) 
 Former 91 (19.0)12 (16.4)21 (20.6)14 (17.5)7 (9.5)14 (28.0)10 (26.3)13 (21.3) 
 Never 177 (37.0)28 (38.4)35 (34.3)31 (38.8)33 (44.6)17 (34.0)12 (31.6)21 (34.4) 
 Social 36 (7.5)3 (4.1)10 (9.8)6 (7.5)8 (10.8)3 (6.0)0 (0.0)6 (9.8) 
 Tumor size, mean (standard deviation), cm4493.86 (2.28)3.78 (2.05)4.36 (2.81)3.80 (2.16)3.27 (1.69)3.97 (2.20)3.43 (2.00)4.05 (2.44)0.234
Metastatic, n (%)275        0.018
 No 150 (54.5)20 (38.5)38 (69.1)20 (47.6)20 (45.5)16 (59.3)12 (66.7)24 (64.9) 
 Yes 125 (45.5)32 (61.5)17 (30.9)22 (52.4)24 (54.5)11 (40.7)6 (33.3)13 (35.1) 
Mucinous, n (%)121        < 0.001
 0 91 (75.2)21 (95.5)20 (57.1)11 (78.6)10 (100.0)11 (100.0)3 (37.5)15 (71.4) 
 1 30 (24.8)1 (4.5)15 (42.9)3 (21.4)0 (0.0)0 (0.0)5 (62.5)6 (28.6) 
Lepidic, n (%)121        0.063
 0 71 (58.7)8 (36.4)21 (60.0)10 (71.4)7 (70.0)10 (90.9)5 (62.5)10 (47.6) 
 1 50 (41.3)14 (63.6)14 (40.0)4 (28.6)3 (30.0)1 (9.1)3 (37.5)11 (52.4) 
Acinar, n (%)121        0.012
 0 78 (64.5)17 (77.3)28 (80.0)8 (57.1)4 (40.0)5 (45.5)7 (87.5)9 (42.9) 
 1 43 (35.5)5 (22.7)7 (20.0)6 (42.9)6 (60.0)6 (54.5)1 (12.5)12 (57.1) 
Micro/papillary, n (%)121        0.175
 0 106 (87.6)21 (95.5)31 (88.6)14 (100.0)7 (70.0)10 (90.9)6 (75.0)17 (81.0) 
 1 15 (12.4)1 (4.5)4 (11.4)0 (0.0)3 (30.0)1 (9.1)2 (25.0)4 (19.0) 
Solid, n (%)121        0.143
 0 103 (85.1)20 (90.9)30 (85.7)11 (78.6)9 (90.0)6 (54.5)8 (100.0)19 (90.5) 
 1 18 (14.9)2 (9.1)5 (14.3)3 (21.4)1 (10.0)5 (45.5)0 (0.0)2 (9.5) 
Mixed, n (%)121        0.492
 0 88 (72.7)19 (86.4)26 (74.3)9 (64.3)8 (80.0)8 (72.7)6 (75.0)12 (57.1) 
 1 33 (27.3)3 (13.6)9 (25.7)5 (35.7)2 (20.0)3 (27.3)2 (25.0)9 (42.9) 
Primary, n (%)428        0.056
 0 233 (54.4)39 (56.5)40 (47.1)41 (57.7)30 (46.2)21 (45.7)22 (62.9)40 (70.2) 
 1 195 (45.6)30 (43.5)45 (52.9)30 (42.3)35 (53.8)25 (54.3)13 (37.1)17 (29.8) 
Stage, n (%)483        < 0.001a
 I 118 (24.4)20 (27.0)26 (25.5)14 (16.9)19 (26.0)16 (32.0)11 (28.9)12 (19.0) 
 II 46 (9.5)1 (1.4)19 (18.6)5 (6.0)4 (5.5)4 (8.0)4 (10.5)9 (14.3) 
 III 108 (22.4)12 (16.2)29 (28.4)27 (32.5)11 (15.1)9 (18.0)5 (13.2)15 (23.8) 
 IV 211 (43.7)41 (55.4)28 (27.5)37 (44.6)39 (53.4)21 (42.0)18 (47.4)27 (42.9) 
FISH, n (%)453        0.042
 Negative 402 (88.7)64 (90.1)92 (96.8)65 (83.3)63 (88.7)35 (81.4)32 (86.5)51 (87.9) 
 Positive 51 (11.3)7 (9.9)3 (3.2)13 (16.7)8 (11.3)8 (18.6)5 (13.5)7 (12.1) 
  1. sTRU Simplified terminal respiratory unit, sPP Simplified proximal-proliferative, sPI Simplified proximal-inflammatory, non-TRUPPPI Mutations in genes other than EGFR, KRAS, and TP53, FISH Fluorescence in situ hybridization
  2. P values are based on Fisher exact test for categorical variables and Kruskal-Wallis rank-sum test for continuous variables
  3. aFisher exact test with Monte Carlo simulation